Figure 3.

Effect of ARE treatment on the morphology of F-actin structures in 4T1 breast cancer cells with DOX chemotherapy: (A) Rhodamine Phalloidin and DAPI (blue) staining of 4T1 breast cancer cells untreated and treated with DOX (10 µg/mL) and ARE (50 µg/mL) plus DOX (10µg/mL). (B) The quantified cell viability of the DOX-treated 4T1 breast cancer cells with ARE treatment was significantly decreased compared to that of those without ARE treatment. Data are shown as the mean ± SEM (N = 3 for each group, ** p < 0.01, one-way ANOVA followed by the Student–Newman–Keuls multiple comparisons post hoc test). Scale bar = 100 μm.